ABOUT
About Ipamorelin Reviews.
An independent editorial project that reads the published record and weighs how strong the evidence actually is.
What this site is
Ipamorelin Reviews is an independent editorial project that publishes summaries and appraisals of the peer-reviewed research literature on ipamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The word "reviews" in our name describes what we do with the literature — we review studies and weigh the strength of their evidence — not a service we provide to a patient. There is no consultation, no prescription, and no product behind this name. It is a reading room for the published record, nothing more.
How we approach the evidence
Our editorial stance is appraisal, not advocacy. Ipamorelin is a useful test case for why that matters: it has a large marketing footprint and a thin evidence base, and the two are easy to confuse. So we lead with what is actually established — the founding selectivity data — and we are equally plain about what failed, most notably the one published Phase 2 trial that missed its endpoint. We separate proven pharmacology from mechanistic plausibility, and we separate both from the anecdotal effects users report. Every quantitative claim on the site is tied to a numbered citation you can check on the references page. Where the evidence is class-level or theoretical rather than ipamorelin-specific, we label it as such rather than letting it read as a finding about ipamorelin.
What we do not do
We do not recommend doses, protocols, or sources, and we do not tell anyone what to take — the site is a digest of research, not guidance for use. We do not name or promote commercial products or brands, and we hold no commercial position in ipamorelin or anything related to it. We do not present anecdotal community reports as proven outcomes; where we relay them, we label them anecdotal. And we do not overstate the science: when the human evidence is one failed trial and one pharmacokinetic study, we say exactly that. The aim is a record a reader can trust precisely because it does not try to sell them anything.